Skip to main
SOPH

SOPH Stock Forecast & Price Target

SOPH Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sophia Genetics is well-positioned to revolutionize the practice of data-driven medicine with its innovative platform and strong partnerships. Their projected growth and plans for achieving profitability demonstrate their potential for long-term success in the healthcare technology industry.

Bears say

Sophia Genetics is currently expanding its work with Memorial Sloan Kettering to form a joint venture and Precision Medicine Hub, which has the potential to enhance its precision oncology capabilities. However, Sophia Genetics has not finalized the JV's details or terms, and its current financials show a decline in revenue per analysis, which may be impacted by headwinds with biopharmaceutical customers. Additionally, Sophia Genetics also faces stiff competition from established players like Guardant Health and Tempus AI, Inc, with the latter having incurred significant losses and debt on its balance sheet.

SOPH has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sophia Genetics SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sophia Genetics SA (SOPH) Forecast

Analysts have given SOPH a Strong Buy based on their latest research and market trends.

According to 2 analysts, SOPH has a Strong Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sophia Genetics SA (SOPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.